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Objective: To investigate associations between peripheral innate immune activation and
frontotemporal lobar degeneration (FTLD) in progranulin gene (GRN) haploinsufficiency.
Methods: In this cross-sectional study, ELISA was used to measure six markers
of innate immunity (sCD163, CCL18, LBP, sCD14, IL-18, and CRP) in plasma from
30 GRN mutation carriers (17 asymptomatic, 13 symptomatic) and 29 controls. Voxel
based morphometry was used to model associations between marker levels and brain
atrophy in mutation carriers relative to controls. Linear regression was used to model
relationships between plasma marker levels with mean frontal white matter integrity
[fractional anisotropy (FA)] and the FTLD modified Clinical Dementia Rating Scale sum
of boxes score (FTLD-CDR SB).
Results: Plasma sCD163 was higher in symptomatic GRN carriers [mean 321 ng/ml
(SD 125)] compared to controls [mean 248 ng/ml (SD 58); p < 0.05]. Plasma CCL18
was higher in symptomaticGRN carriers [mean 56.9 pg/ml (SD 19)] compared to controls
[mean 40.5 pg/ml (SD 14); p < 0.05]. Elevation of plasma LBP was associated with white
matter atrophy in the right frontal pole and left inferior frontal gyrus (p FWE corrected
<0.05) in all mutation carriers relative to controls. Plasma LBP levels inversely correlated
with bilateral frontal white matter FA (R2 = 0.59, p= 0.009) in mutation carriers. Elevation
in plasma was positively correlated with CDR-FTLD SB (b = 2.27 CDR units/µg LBP/ml
plasma, R2 = 0.76, p = 0.003) in symptomatic carriers.
Conclusion: FTLD-GRN is associated with elevations in peripheral biomarkers of
macrophage-mediated innate immunity, including sCD163 and CCL18. Clinical disease
severity and white matter integrity are correlated with blood LBP, suggesting a role for
peripheral immune activation in FTLD-GRN.
Keywords: progranulin (GRN), frontotemperal lobar degeneration, monocyte, innate immune system, peripheral
immune activation
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INTRODUCTION
Haploinsufficiency of the progranulin gene (GRN) is a
major cause of familial frontotemporal lobar degeneration
(FTLD), giving rise to a variety of fatal and untreatable
frontotemporal dementia (FTD-GRN) syndromes (1).
Progranulin has a broad role in vertebrates, including regulation
of lysosomal function, angiogenesis, blood monocytes, and
brain microglia (2, 3). In patients with FTD-GRN, there
is an increased rate of autoimmunity (4), suggesting that
peripheral immune dysregulation is a feature of this disease.
In Grn−/− mice, peripheral myeloid cells and microglia release
excessive pro-inflammatory cytokines in response to bacterial
lipopolysaccharide (LPS), and both sets of mononuclear cells
exhibit heightened neurotoxicity (3). Moreover, Grn−/− mice
display poor reconstitution of the blood brain barrier after injury
(5). If humans recapitulate animal models of familial FTLD,
patients with GRN deficiency are likely to have hyperactive
monocytes, with less restricted access to the central nervous
system (CNS) and greater capacity for neuronal injury. Plasma
biomarkers of innate immune activation may therefore provide
evidence for a potentially treatable monocyte-driven mechanism
of pathogenesis in GRN deficiency and serve as measures of drug
response in future clinical therapeutic trials targeting myeloid
cells. Additionally, given the documented relationship between
peripheral inflammation and white matter integrity outside of
FTD cohorts (6), abnormal peripheral monocyte activation may
serve to explain the unique burden of white matter disease that
distinguishes FTD-GRN from other familial FTD syndromes (7).
Six specific candidate plasma biomarkers of innate immune
activation were selected for investigation in patients with
GRN mutations (Figure 1). Lipopolysaccharide binding protein
(LBP) and soluble Cluster of Differentiation 14 (sCD14) (8)
were selected as candidate biomarkers due to their roles as
important cofactors in toll-like receptor 4 (TLR4) activation via
bacterial endotoxin (a trigger of excessive myeloid activation
in Grn−/− mice) (3). In contrast to LPS and sCD14, plasma
interleukin 18 (IL18), a marker of the inflammasome pathway
(10), was selected as a marker of monocyte activation via a
TLR4 independent pathway. Soluble cluster of differentiation 163
(sCD163), a protein cleaved from recently activated monocytes,
was selected as an established general marker of ongoing
monocyte activation and turnover (9). Additionally, chemokine
(C-C motif) ligand 18 (CCL18), a marker of non-classical
(potentially anti-inflammatory) monocytes (12), was selected as
indicator of chronic phenotypic transition away from classical
monocyte forms (a shift common to many chronic inflammatory
states). Finally, C-reactive protein (CRP), an acute phase reactant,
was also assessed as a non-specific biomarker of immune
activation. Our approach provides early evidence that peripheral
innate immune activation is a feature of GRN haploinsufficiency
and a potential mediator of FTD-GRN pathogenesis.
METHODS
Patient Selection
Patient demographics are summarized in Table 1. 30 individuals
with known GRN mutations (17 asymptomatic and 13
symptomatic) and 29 age-matched controls were recruited
through the University of California San Francisco Memory and
Aging Center between 2009 and 2016. Our controls were not
family members of mutation carriers. Patients were classified as
“symptomatic” if they met criteria for mild cognitive impairment
(13) or experienced loss of functional independence from a
neurodegenerative syndrome. Within the symptomatic GRN
mutation carrier cohort, seven individuals met consensus criteria
for bvFTD (14), one met criteria for mild cognitive impairment
(13) (with a progressive dysexecutive/behavioral syndrome),
three met consensus criteria for a PPA (15), one had an amnestic
syndrome resembling Alzheimer’s disease (with a negative
amyloid PET scan), one presented with idiopathic parkinsonism,
and one individual suffered from a multifactorial dementia
syndrome with behavioral, memory, language, and visuospatial
impairments. Among the three participants who met criteria for
PPA, one met criteria for the non-fluent variant of PPA (nfvPPA),
and two presented with mixed PPA syndromes which could not
be further subcategorized. This array of heterogeneous clinical
syndromes was consistent with the known clinical heterogeneity
of symptomatic GRN haploinsufficiency (1). Participants
included in this study did not have any documented history
of immunosuppression, autoimmune disease, hypothyroidism,
acute infection, chronic infection, or positive biomarkers
consistent with Alzheimer’s pathology (including cerebrospinal
fluid Amyloid Beta 42 or Amyloid beta PET with an FDA
approved ligand) on retrospective review of their medical
history. Only one GRN mutation carrier was excluded from
our analyses, due to a positive amyloid PET scan. One control
participant was also excluded from our analyses, due to the
presence of autoimmune disease requiring immunosuppression.
This study was approved by the UCSF Institutional Review
Board (IRB), and all participants gave informed consent.
Plasma Marker Levels
Six selected plasma biomarkers of innate immune activity
were measured (sCD163, CCL18, sCD14, LBP, CRP, IL18)
(Figure 1). No other fluid biomarkers were analyzed for this
study. Our biomarkers of interest were not uniformly available in
commercial multiplex panels, so each biomarker was measured
individually by ELISA at a contract research organization (CRO)
(Assaygate, Inc., Ijamsville, MD). Biomarkers were measured
from frozen plasma, which was collected within 90 days of clinical
and radiographic data. Samples were deidentified and randomly
arranged across cohorts before being sent to the CRO.
MRI Image Acquisition and Processing
The majority of T1 MR and diffusion tensor brain images were
obtained at UCSF via the same 3 Tesla Siemens Tim Trio
system with a 12-channel head coil. A single control participant’s
T1 images were obtained at UCSF via a 3 Tesla Siemens
Prisma System under an equivalent harmonized protocol.
Image acquisition was performed under previously published
parameters (16, 17) as discussed in Supplemental Methods.
After a quality control review, 22 controls, 14 asymptomatic
carriers, and 11 symptomatic carriers had valid T1 weighted MR
imaging within 90 days of their plasma collection, and of these
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FIGURE 1 | Abbreviated summary of monocyte activation pathways. Proteins depicted as red ovals were selected as candidate markers of monocyte activation.
Bacterial lipopolysaccharide (LPS) requires the presence of LBP (lipopolysaccharide binding protein) and sCD14 (soluble cluster of differentiation 14), to TLR4 (toll-like
receptor 4) and the NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) (8). Activating monocytes cleave surface CD163 (Cluster of Differentiation
163) in to a soluble form (sCD163) (9). Monocytes may also be activated by pathogen-associated molecular patterns (PAMPS) which lead to release IL-18 via the
inflammasome pathway (10). Classical monocytes (CD14+, CD16−) eventually transition to intermediate (CD14+CD16+) and eventually non-classical monocytes
(CD14low, CD16+) (11), the latter of which are a source of CCL18 (chemokine C-C motif ligand 18) (12).
cases 17 controls, 12 asymptomatic carriers, and 10 symptomatic
carriers had valid diffusion tensor imaging.
T1-weighted images underwent segmented in SPM12
(Wellcome Trust Center for Neuroimaging, London, UK,
www.fil.ion.ucl.ac.uk/spm) were used to create a study specific
template using DARTEL (18), smoothed using a 6mm Gaussian
FWHM kernel. Each study participant’s segmentation was
inspected to ensure the robustness processing. Volumes in
specific brain regions of interest (ROI) were calculated by
transforming a standard parcellation atlas (19) into ICBM space
and summing all gray matter within each parcellated region.
Diffusion images initially underwent denoising (20) and were
realigned using the FSLMCFLIRT algorithm (21). The Dipy non-
linear least-squares algorithm (22) was used to calculate diffusion
tensors (DT), and a study specific template was created through
iterative linear and non-linear registration of diffusion tensor
images. Once in groupwise space, DT images were diagonalized
into eigenvectors from which fractional anisotropy (FA) maps
were calculated. Frontal and temporal regions of interest with
extracted using the ICVM-DTI-81 white matter labels and tract
atlas (23).
Volumetric Analysis
Voxel-based statistics were performed in SPM12 and used to
investigate relationships between brain volume and plasmas
marker of interest. Contrasts modeled an interaction between
GRN mutation carrier status and each inflammatory biomarker
level in determining burden of atrophy across all cases. Clusters
and voxels with a SPM familywise error (FWE) corrected p-
value <0.05 were considered significant. To further explore the
relationship between brain volume and plasma markers, each
cluster with significant constituent peak voxels in VBM analysis
was used to define a tailored (ROI). Composite frontotemporal
regions of interest were also created by summing volumes
within individual right frontal, left frontal, right temporal, and
left temporal gray mater regions of interest from a standard
parcellation atlas (19) transformed into ICBM space. Linear
regression analysis was used in GRN mutation carriers to
Frontiers in Neurology | www.frontiersin.org 3 September 2019 | Volume 10 | Article 1004
Ljubenkov et al. Immune Activation in GRN Haploinsufficiency
TABLE 1 | Patient demographics, plasma biomarkers, and radiographic
measures.
Controls GRN mutation carriers
Asymptomatic Symptomatic
Total (N) 29 17 13
Volumetric MRI (N) 22 14 11
DTI imaging (N) 17 12 10
Female/male 16/13 8/9 7/6
Mean (SD) Mean (SD) Mean (SD)
Age 57.4 (13) 54.4 (11) 62(7)
Plasma markers
Plasma sCD163 (ng/ml) 248 (58) 273 (91) 321 (125)†
Plasma CCL18 (pg/ml) 40.5 (14) 54.2 (26) 56.9 (19)†
Plasma sCD14 (µg/ml) 1.60 (2) 1.45 (0.3) 1.68 (3)
Plasma LBP (µg/ml) 9.62 (5) 8.92 (2) 9.57 (2)
Plasma CRP (µg/ml) 2.07 (3) 1.80 (2) 1.82 (2)
Plasma IL18 (pg/ml) 26.3(12) 25.4 (9) 30.2 (17)
Clinical measures
CDR-FTLD SB 0.06 (0.2) 0.64 (0.8)† 8.7 (7)†‡
FAQ total 0 (0) 0.6 (1.9) 14.1 (12)†‡
CGIS 1 (0) 1.2 (0.4) 4.0 (1)†‡
MMSE total 29.4 (1) 28.9 (1) 19.3 (10)†‡
CVLT immediate recall 8.4 (0.8) 7.8 (1) 5.1 (3)†‡
CVLT delayed recall 8.4 (0.9) 7.7 (1) 5.0 (3)†‡
CVLT D1 3.3 (0.3) 3.4 (0.3) 2.2 (1.5)†‡
Boston naming test 12.9 (2) 11.6 (3) 9.6 (4)†
Lexical fluency (D-words) 15.8 (4) 15.8 (5) 10.1 (6)†
Semantic fluency (animals) 23.8 (6) 24.2 (6) 15.3 (7)†‡
Forward digit span 7.1 (1) 7.1 (1) 5.0 (2)
Backward digit span 5.9 (1) 5.1 (1) 3.3 (1)†‡
Stroop color naming 14.3 (1) 13.7 (1) 11.3 (4)
Stroop interference 91.4 (14) 81.8 (17) 63.4 (24)†
Modified trails time 22.4 (12) 26.4 (9) 55.3 (34)†‡
Modified rey figure copy 15.7 (0.7) 15.4 (1.3) 14.4 (1.3)†‡
Volumetric MRI
Whole brain volume (cm3) 617 (68) 589 (75) 492 (81)†‡
Left frontal cortex (cm3) 54 (6) 50.7 (6) 40.1 (9)†‡
Right frontal cortex (cm3) 51.7 (6) 48.2 (5) 39.1 (10)†‡
Left temporal cortex (cm3) 29.0 (3) 27.3 (3) 22.7 (3)†
Right temporal cortex (cm3) 28.7 (3) 26.7 (3) 22.7 (5)†‡
Bifrontal average FA 0.45 (0.03) 0.46 (0.02) 0.37 (0.27)†‡
Left frontal average FA 0.43 (0.03) 0.44 (0.03) 0.35 (0.27)†‡
Right frontal average FA 0.42 (0.03) 0.43 (0.03) 0.35 (0.27)†‡
Corpus callosum genu FA 0.56 (0.3) 0.56 (0.2) 0.44 (0.09)†‡
†
Indicates values significantly differed from control (p < 0.05, uncorrected).
‡
Indicates values significantly differed from asymptomatic GRN mutation carriers (p <
0.05, uncorrected).
CCL18, chemokine C-C motif ligand 18; CDR-FTLD SB, frontotemporal lobar
degeneration specific clinical dementia rating scale sum of boxes score; CGIS, Clinical
Global Impression Severity score; CRP, C-reactive protein; CVLT, California Verbal
Learning Test; D1, D prime; DTI, diffusion tensor imaging; FAQ, Functional Activities
Questionnaire; IL-18, interleukin 18; LBP, lipopolysaccharide binding protein; MMSE, Mini-
Mental Status Exam; sCD14, soluble Cluster of Differentiation 14; sCD163, soluble Cluster
of Differentiation 163; SD, standard deviation.
compare plasma markers with volume in the tailored ROIs, the
whole brain (excluding CSF spaces), and in composite frontal
and temporal ROIs. Linear regression analysis was also used
in GRN mutation carriers to compare plasma biomarkers with
gray matter asymmetry (the absolute value of total right gray
matter volume subtracted from total left gray matter volume)
and white matter asymmetry (the absolute value of total right
white matter volume subtracted from total left white matter
volume). Additionally, linear regression analysis was used to
model an interaction between biomarkers and clinical status
(symptomatic vs. asymptomatic) in determining volume in our
tailored ROIs. Age, sex, and total intracranial volume (TIV)
were used as covariates in all voxel-based statistics and linear
regression analyses.
Diffusion Tensor Imaging (DTI) Analyses
Using a hypothesis-based approach (based on the distribution
of white matter findings in our VBM analysis) a composite
bifrontal lobar region of interest (ROI) was generated, averaging
fractional anisotropy (FA) values across the bilateral superior
longitudinal fasciculus, the bilateral cingulum cingulate, and the
genu of the corpus callosum. Linear regression models assessed
the correlation between bifrontal FA and individual plasma
markers. Additional analyses focused on LBP (the sole marker
with a linear relation to bifrontal FA) and FA in constituent
regions of interest: the right and left frontal ROIs (superior
longitudinal fasciculus and cingulum bundle), the right and
left superior longitudinal fasciculus, the right and left cingulum
bundle, and the genu of the corpus callosum. Age and sex were
used as covariates in all VBM and linear regression analyses.
A familywise error correction (Šidák correction) was applied to
analysis across multiple constituent ROIs.
Clinical Assessments
Clinical disease severity was primarily assessed using the FTD-
specific clinical dementia rating scale sum of boxes score
(FTLD-CDR SB) (24). Clinical severity was also assessed vis
the Functional Activities Questionnaire (FAQ) (25), the Clinical
Global Impression Severity score (CGIS) (26), the Mini-Mental
State Examination (MMSE) (27) the 9 item California Verbal
Learning Test (CVLT) (28), Boston Naming Test (BNT) (29),
phonemic fluency (D-words/minute) (30), semantic fluency
(animals/minute) (31), digit span (forward and backward) (32),
the Stroop color naming and inhibition tasks (33), the Modified
Trails Test (30), and the Modified Rey Figure Copy (30).
A familywise error correction (Šidák correction) was then
applied (across multiple cognitive measures) as a follow up
sensitivity analysis.
Statistical Analysis
Statistical analysis was performed using Stata R©, version 14.2.
The normality of plasma marker distributions was assessed via
the skewness kurtosis test (34). Non-normally distributed values
(LBP, CRP, and IL18) were compared using non-parametric
methods, including the Kruskal-Wallis test followed by post-
hoc Wilcoxon pairwise rank sum testing. All other markers
(sCD163, CCL18, and sCD14) were compared between our
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3 groups with Analysis of Variance (ANOVA), followed by a
post-hoc pairwise Tukey test to correct for multiple pairwise
comparisons. We did not additionally adjust for multiple
comparisons between differing biomarkers, as individual group-
wise findings should be allowed to support each other rather
than detract from each given the biological interrelation of
biomarkers expressed in Figure 1. Additionally, our project was
intended to identify potential biomarkers of interest and their
interrelationships for future studies, so we elected to minimize
the chance of type II error. Linear regression models were fit
to examine the relationship between FTLD-CDR SB or other
clinical assessments and individual plasma biomarkers. Analyses
were restricted to symptomatic carriers for measures that were
at floor in asymptomatic carriers (CDR-FTLD SB, CGIS). Age
and sex were included as covariates in all models. As a follow
up sensitively analysis, a familywise error correction (Šidák
correction) was applied for regression analyses repeated across
six different biomarkers.
Patient and Public Involvement
This research study utilized clinical data and specimens
previously collected at the University of California Memory and
Aging Center. Patients were therefore not directly involved in
determining the design, research questions, outcome measures,
recruitment, conduct or assessment of burden in this study.
RESULTS
Group Differences in Clinical, Biomarker,
and Imaging Measures
Patient demographics are summarized in Table 1. Normal
controls, asymptomatic GRN mutation carriers, and
symptomatic GRN carriers did not differ significantly in
age. Asymptomatic mutation carriers had slightly higher
CDR-FTLD-SB than controls (p = 0.0011 Tukey corrected),
but these two cohorts did not differ in any other collected
clinical or radiographic measures. Symptomatic FTD-GRN
patients differed from controls and asymptomatic carriers across
the majority of clinical and radiographic measures assessed
(Table 1). Symptomatic GRN mutation carriers displayed high
sCD163 (p = 0.031 Tukey corrected) and CCL18 (p = 0.038
Tukey corrected) concentrations relative to controls (Figure 2,
Table 1). Plasma concentrations of CD14, LBP, CRP, or IL-18 did
not differ between groups.
Inflammatory Biomarkers Reflect Clinical
Severity
Among patients with symptomatic disease, there was a positive
linear relationship between plasma LBP concentrations and
CDR-FTLD SB (b = 2.27 CDR units/µg LBP/ml plasma, 95%
CI [1.02, 3.51], p = 0.003 uncorrected, R2 = 0.76) (Figure 3)
and the FAQ (b = 3.74 FAQ units/ µg LBP/ml Plasma,
95% CI [1.36, 6.11], p = 0.007 uncorrected, R2 = 0.68).
There was a trend toward correlation between CRP levels
and FTLD-CDR SB, but that finding did not survive multiple
comparisons (R2 = 0.67, p = 0.01 uncorrected). There was
no relationship between CDR-FTLD and other plasma markers
including sCD163, sCD14, CCL18, and IL-18 in symptomatic
GRNmutation carriers. Plasma biomarker levels did not correlate
with other clinical assessments.
Plasma Biomarkers and Brain Atrophy
VBM revealed multiple frontal-predominant clusters (in white
matter more than gray matter) where elevated markers of
inflammation were associated with more severe atrophy in GRN
mutation carriers (Table 2). Elevated LBP was associated with
decreased white matter in the left frontal pole (p < 0.001, FWE
corrected), right inferior operculum (p= 0.006, FWE corrected),
and right anterior internal capsule (p < 0.001, FWE corrected)
(Figure 4). Elevated LBP was also associated with decreased
gray matter in the left anterior frontal pole (p = 0.002, FWE
corrected). There was a nearly significant association between
elevated plasma sCD14 and decreased white matter integrity in
the left middle temporal gyrus (p = 0.05, FWE corrected), and
elevated plasma IL-18 was associated with decreased gray matter
in the middle occipital gyrus (p= 0.033, FWE corrected).
In order to better assess the relationship between plasma
LBP and white matter integrity, two additional volumetric ROIs
(left frontal pole white matter and right inferior operculum
white matter) were generated from significant clusters in VBM
analyses. Within GRN carriers, there was a linear relationship
between elevated plasma LBP and more severe white matter
atrophy in a left frontal pole ROI white matter ROI (b = −8.59
mm3/mg LBP/ ml plasma, 95% CI [−10.6, −1.26], R2 = 0.84,
p = 0.024 uncorrected) and right inferior frontal operculum
white matter ROI (b= −38.9 mm3/mg LBP/ ml plasma, 95%
CI [−63.6, −14.2] R2 = 0.86, p < 0.001 uncorrected,), LBP,
sCD14, and IL-18 did not correlate with whole brain volume
or frontotemporal composites. All six plasma biomarkers of
interested did not correlate with gray matter asymmetry or
white matter asymmetry. There was no interaction between
plasma LBP and clinical status (symptomatic vs. asymptomatic)
in determining volume in our tailored volumetric ROIs in
mutation carriers.
Plasma Biomarkers and White Matter
Integrity
We used DTI measurements of fractional anisotropy (FA) to
further investigate the relationship between plasma LBP and
white matter integrity. Elevated LBP was related to decreased
fractional anisotropy (FA) in the bilateral frontal lobes (b =
−0.016 FA/µg/ml LBP, R2 = 0.59, p = 0.009 uncorrected) in
GRN mutation carriers (Figure 3C, Table 3). LBP elevation was
also associated with decreased FA within multiple constituent
regions of interest, including a left frontal lobe composite
region of interest (p = 0.004 uncorrected), a right frontal
composite region of interest (p = 0.026 uncorrected), the
genu of the corpus callosum (p = 0.027 uncorrected), the
left cingulum cingulate (p = 0.003 uncorrected), the right
cingulum cingulate (p = 0.02 uncorrected), and the left superior
longitudinal fasciculus (p = 0.015 uncorrected). The association
between LBP and FA remained significant in the left cingulum
cingulate and left frontal lobe composite ROI after correction for
multiple comparisons.
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FIGURE 2 | Plasma markers of innate immunity by clinical group. Circles represent individual people in the study. Whiskers represent the highest and lowest adjacent
values (±1.5 × interquartile range) with a median line in between. The p-values associated with brackets for the sCD163 and CCL18 plots are post-hoc pairwise
Tukey tests (after ANOVA p < 0.05) between controls and symptomatic carriers.
DISCUSSION
We identified a direct correlation between disease severity
and a plasma mediator of the peripheral innate immune
response (LBP) in GRN mutation carriers (symptomatic and
asymptomatic). Additionally, we identified an elevation in
plasma biomarkers of ongoing monocyte turnover (sCD163)
and chronic monocyte activation (CCL18) in symptomatic GRN
mutation carriers (though not asymptomatic mutation carriers)
relative to controls.
Our results potentially represent early evidence for a
neuro-inflammatory model of FTD-GRN progression,
in which the peripheral innate immune systems directly
contributes to brain pathology. In particular, our findings
indicate a possible relationship between the peripheral
immune system and white matter disease in GRN mutation
carriers. Alternatively, it is possible that our results represent
parallel autonomous processes in the peripheral immune
system and CNS or peripheral inflammation in response to
CNS neuropathology.
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FIGURE 3 | Plasma LBP correlates with white matter integrity and clinical severity. Circles represent uncorrected plotted values for individual GRN mutation carriers
within our study, with yellow circles representing asymptomatic individuals and red circles representing symptomatic individuals. The left frontal (A) and right frontal (B)
regions of interest (ROIs) depicted were defined by the left frontal pole white matter and right inferior frontal operculum white mater clusters described in Table 2. A
linear regression line [controlling for age and sex, as well as total intracranial volume (TIV) for models with volumetric measures] with a gray 95% confidence interval
has been superimposed on each plot [(A) R2 = 0.85, p = 0.024 uncorrected; (B) R2 = 0.86, p < 0.0005 uncorrected; (C) R2 = 0.59, p = 0.009; (D) R2 = 0.75, p =
0.003 uncorrected].
White matter T2 hyperintensities are well described in FTD-
GRN, and neuroinflammation has previously been proposed as
a mechanism for these lesions (7). In Grn−/− mice, microglia
exert a pathogenic effect on neurons (8) due in part to excessive
compliment-mediated synaptic destruction (35). A similar
process of synaptic destruction, either through direct infiltration
of monocytes or secondary activation of glial cells (36), may
explain the relationship between peripheral inflammation and
white matter in our study. Activation of the peripheral immune
system, particularly of monocytes, is known to induce secondary
activation of microglia (36) outside of FTDmodels. Additionally,
FTD-GRN may involve blood-brain barrier dysfunction (5),
which could increase the interaction between peripheral and
central innate immune cells. White matter change in FTD-
GRN may also reflect the anatomical distribution of perivascular
macrophages (on the front line of interaction with the peripheral
immune system) aligning deep penetrating small vessels.
Plasma LBP is an acute phase reactant released by the liver
(8) and is unlikely to faithfully track monocyte activation
downstream. The correlation between plasma LBP and white
matter changes may, however, reflect a specific upstream
mechanism of monocyte activation in GRN mutation
carriers. Plasma LBP is an essential factor for activation of
monocytes by bacterial endotoxins via the toll-like receptor
4 (TLR4) (8). The correlation between LBP and disease
may therefore reflect the role of external antigens, such as
endotoxins from gut microbes, in promoting FTD-GRN. Grn
knockout (Grn−/−) mice exhibit poor clearance of bacterial
pathogens and hyper-activation to bacterial LPS via TLR4
(3). Patients with GRN haploinsufficiency may similarly
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TABLE 2 | Brain atrophy is associated with elevated plasma markers in GRN carriers.
Marker Region Description Cluster Peak voxel Voxel location (mm) X Y Z
p (FWE corrected) T score Z score
LBP White matter Left frontal pole 0.000 6.59 5.41 −27 45 −11
LBP White matter Right inferior operculum 0.006 5.72 4.87 45 15 20
LBP White matter Right anterior internal capsule and adjacent white matter 0.000 4.58 4.09 17 26 5
LBP Gray matter Left anterior inferior frontal gyrus and orbitofrontal gyrus 0.002 4.5 4.03 −33 30 −12
sCD14 White matter Left middle temporal gyrus 0.050 5.18 4.52 −35 5 −41
IL-18 Gray matter Left middle occipital gyrus 0.033 5.35 4.63 −36 −81 39
FWE, familywise error; IL-18, interleukin 18; LBP, lipopolysaccharide binding protein; sCD14, soluble Cluster of Differentiation 14; VBM, voxel based morphometry. A FWE corrected
alpha ≤ 0.05 was used to define significance.
FIGURE 4 | Brain atrophy associated with elevated plasma LBP in GRN carriers. Abbreviations: FWE, familywise error; LBP, lipopolysaccharide; unc, uncorrected.
Note: The depicted clusters were obtained via voxel-based morphometry (VBM) analysis modeling an interaction between GRN mutation carriers status and plasma
LBP in determining atrophy in our study cohort (including controls and mutation carriers).
experience dysfunctional inflammation, with poor clearance
of bacterial pathogens despite excessively robust monocyte
activation. Under this model, GRN mutation carriers and
healthy controls would experience very different sustained
monocyte responses in reaction to the same inflammatory
challenge. This may explain why LBP correlated with disease
in mutation carriers, even though LBP levels were similar
to controls.
Plasma sCD163 and CCL18, unlike LBP, are directly released
from monocytes and represent differing aspects of monocyte
function. After monocytes are activated (by LPS or other
triggers), they cleave membrane-bound CD163 and release the
Frontiers in Neurology | www.frontiersin.org 8 September 2019 | Volume 10 | Article 1004
Ljubenkov et al. Immune Activation in GRN Haploinsufficiency
TABLE 3 | Bifrontal DTI measures correlate with plasma LBP in GRN mutation
carriers.
b (FA
/µg/ml)
[95%
conf.]
R2 p
Bi-frontal (FA) −0.013 (−0.023,
−0.004)
0.59 0.009
Constituent regions of interest
Left frontal (FA) −0.013 (−0.022,
−0.005)
0.61 0.004†
Right frontal (FA) −0.01 (−0.019,
−0.001)
0.57 0.026
Genu of the corpus callosum −0.019 (−0.035,
−0.003)
0.47 0.027
Left cingulum cingulate −0.018 (−0.028,
−0.007)
0.61 0.003†
Right cingulum cingulate −0.011 (−0.020,
−0.002)
0.61 0.02
Left superior longitudinal fasciculus −0.009 (−0.016,
−0.002)
0.54 0.015
Right superior longitudinal fasciculus −0.009 (−0.0179,
0.0002)
0.46 0.056
†
Denotes findings that remained significant after a follow up familywise error correction;
alpha ≤ 0.0073.
DTI, diffusion tensor imaging; CI, confidence interval; FA, fractional anisotropy; LBP,
lipopolysaccharide binding protein.
The presented regression analyses results were controlled for age and sex, and the
presented R2 values apply to the entire model. All p-values are presented in their
uncorrected form.
soluble form (sCD163) (9). Inmodels of encephalitis, sCD163 has
been used as a proxy for monocyte migration to the site of brain
inflammation (37). After stimulation, classical monocytes either
leave circulation or transition to intermediate and eventually
to non-classical forms (11). A sustained peripheral shift in
monocyte phenotypes, away from classical monocyte forms, is
a hallmark of a variety of chronic infections and autoimmune
diseases (38). CCL18 is released chiefly by myeloid cells and has
long been described as a marker of non-classical monocytes (12).
Taken together, elevation of sCD163 and CCL18 in symptomatic
FTD-GRN hint at a chronic inflammatory state, in which classical
peripheral monocytes are chronically migrating to sites of
inflammation and transitioning to non-classical forms in parallel.
In the context of our findings pertaining to LBP, this chronic
activation state may be driven in part by bacterial endotoxin.
This study had several limitations. Voxel-based morphometry
is a technique that is chiefly used to analyze gray matter volumes,
and the majority of our volumetric findings are in white matter
regions of interest. Fortunately, fractional anisotropy provided an
alternate modality that confirmed associations between LBP and
white matter integrity. Additionally, heterogeneous asymmetry
may have limited our ability to find associations between brain
volume and biomarkers using a voxel-based approach. For
this reason, it is possible that larger follow up studies would
identify more extensive bifrontal volume regions associated
with plasma marker of innate immune activation. Our findings
were limited to a relatively small cohort of mutation carriers,
given the rarity of GRN haploinsufficiency and the accessibility
of biospecimens. Interpretation of our findings would greatly
benefit from replication in a separate larger cohort. Our imaging
analysis merged all mutation carriers (pre and post symptomatic)
into one cohort to make inferences about the entire clinical
spectrum of GRN haploinsufficiency. A larger clinical study will
allow for greater distinction between immune phenomena in
asymptomatic mutation carriers and FTD-GRN. Because our
data were from single time points in each participant, it is difficult
to discern what proportion of variance in each plasma marker
is due to sustained inflammation vs. short-term fluctuations in
inflammatorymarkers related to transient stressors. Longitudinal
data would therefore improve our ability to make inferences
about the relationship between inflammatory markers and
disease severity in GRN mutation carriers. Additionally, our
study used a small set of relatively specific plasma markers to
make specific inferences about differing aspects of myeloid cell
behavior and activity. Follow-up studies would ideally include
methods that more directly assess innate immune cells in GRN
mutation carriers. Future studies should seek to assess less
specific biomarkers of inflammation, given previous evidence of
high peripheral tumor necrosis factor alpha (TNF-α) (4) and
Interleukin 6 (IL-6) (39) in patients withGRN haploinsufficiency.
This study highlights the potential value of blood
biomarkers of innate immunity as tools to understand
disease pathogenesis in GRN mutation carriers. Analysis
of longitudinal datasets such as Longitudinal Evaluation
of Familial Frontotemporal Dementia Subjects (LEFFTDS)
and the Genetic FTD Initiative (GENFI) will ultimately
help to determine the temporal relationship between
inflammatory biomarker elevation, clinical severity, and
neuroimaging changes in GRN mutation carriers. The current
findings also suggest that clinical trials of agents that reduce
monocyte/macrophage or microglial activation might help to
elucidate the relationship between inflammation and disease in
GRN mutation carriers and could potentially be used to prevent
or treat FTD-GRN.
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